Last reviewed · How we verify
Giant papillary conjunctivitis
Approved treatments
- Intal · Pfizer
- Cromoglicate · LEO Pharma
- Cromoglycate · Vishwajit Nimgaonkar, MD PhD
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Giant papillary conjunctivitis patent landscape — cliff calendar, originator estates, attackable patents
- Giant papillary conjunctivitis treatment landscape brief
- Giant papillary conjunctivitis treatment updates RSS
Frequently asked questions about Giant papillary conjunctivitis
What drugs treat Giant papillary conjunctivitis?
Tracked treatments include Intal, Cromoglicate, Cromoglycate.
What is the treatment for Giant papillary conjunctivitis?
Standard treatment for Giant papillary conjunctivitis includes Intal, Cromoglicate, Cromoglycate. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Giant papillary conjunctivitis patent cliff · Giant papillary conjunctivitis CI report
- Treatment: Intal · Pfizer
- Treatment: Cromoglicate · LEO Pharma
- Treatment: Cromoglycate · Vishwajit Nimgaonkar, MD PhD
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing